Patients' Perceptions of Subcutaneous Delivery of Darbepoetin Alfa by Autoinjector Prefilled Pen Versus Prefilled Syringe: A Randomized, Crossover Study

Clinical Therapeutics

Volumn 34, Issue 9, 2012, Pages 1948-1953

  Lim, Wai H ^a,b   Chan, Doris ^a,b   Boudville, Neil ^a,b   Pellicano, Susan ^a   Herson, Helen ^a   Moody, Harry ^a   Hutchison, Brian ^a   Snedeker, Marianne ^a   Dogra, Gursharan ^a  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin alfa; Injection; Preference; Subcutaneous

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; ANEMIA; ARTICLE; AUTOINJECTOR PREFILLED PEN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT PREFERENCE; PATIENT SATISFACTION; PERCEPTION; PREFILLED SYRINGE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

AGED; ANEMIA; CROSS-OVER STUDIES; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PAIN; PATIENT PREFERENCE; PATIENT SATISFACTION; QUESTIONNAIRES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84866174673     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.07.012     Document Type: Article

References (33)

1. Nangaku M., Fliser D. Erythropoiesis-stimulating agents: past and future. Kidney Int Suppl 2007, (Suppl):S1-S3.
2. Soni R.K., Weisbord S.D., Unruh M.L. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2010, 19:153-159.
3. Dowling T. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. Am J Health Syst Pharm 2007, 64(Suppl 8):S3-S7.
4. Finkelstein F.O., Story K., Firanek C., et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009, 4:33-88.
5. Kimel M., Leidy N.K., Mannix S., Dixon J. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia?. Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 2008, 11:57-75.
6. Kivitz A., Segurado O.G. HUMIRA pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab. Expert Rev Med Devices 2007, 4:109-116.
7. Clinical guidelines. Anaemia management in chronic kidney disease: (CG39). Issued September. 2006. National Institute for Health and Clinical Excellence.
8. Carrera F., Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus 2009, 2(Suppl 1):i9-i17.
9. Kutner N.G., Zhang R., McClellan W.M., Cole S.A. Psychosocial predictors of non-compliance in haemodialysis and peritoneal dialysis patients. Nephrol Dial Transplant 2002, 17:93-99.
10. Mahon A., Docherty B. Renal anaemia-the patient experience. EDTNA ERCA J 2004, 30:34-37.
11. Nicoletta P., Bernardini J., Dacko C., et al. Compliance with subcutaneous erythropoietin in peritoneal dialysis patients. Adv Perit Dial 2000, 16:90-92.
12. Wazny L.D., Stojimirovic B.B., Heidenheim P., Blake P.G. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002, 40:623-628.
13. Hoggard J., Crouch T., McMurray S., et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 2006, 22:2023-2030.
14. Hertel J., Locay H., Scarlata D., et al. Darbepoetin alfa administered every other week maintains haemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from Simplify the Treatment of Anemia with Aranesp (STAAR). Am J Nephrol 2006, 26:149-156.
15. Hertel J.E., Locay H.R., Scarlata D.S., et al. Darbepoetin alfa administration to achieve and maintain target haemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 2006, 81:1188-1194.
16. Toto R.D., Pichette V., Navarro J., et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004, 24:453-460.
17. Ling B., Walczyk M., Agarwal A., et al. Darbepoetin alfa administered once monthly maintains haemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 2005, 63:327-334.
18. Agarwal A., Silver M.R., Walczyk M., et al. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. J Am Med Dir Assoc 2007, 8:83-90.
19. Agarwal A., Silver M., Reed J. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Int Med 2006, 260:577-585.
20. Disney A., Jersey P., Kirkland G., et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study. Nephrology 2007, 12:95-101.
21. Martinez Castelao A., Reyes A., Valdes F., et al. Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis. Nefrologia 2003, 23:114-124.
22. Del Vecchio L., Villa G., Carraro G., et al. Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO). G Ital Nefrol 2004, 21:259-266.
23. Vanrenterghem Y., Bárány P., Mann J.F., et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002, 62:2167-2175.
24. Carrera F., Oliveira L., Maia P., et al. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2006, 21:2846-2850.
25. Mann J., Kessler M., Villa G., et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol 2007, 67:140-148.
26. Roger S.D., Suranyi M.G., Walker R.G. A randomized, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. Curr Med Res Opin 2008, 24:2181-2187. COMFORT study group.
27. Schmitt C., Nau B., Brummer C., et al. Increased injection pain with darbepoetin- compared to epoetin-ß in paediatric dialysis patients. Nephrol Dial Transplant 2006, 21:3520-3524.
28. Kivitz A., Cohen S., Dowd J.E., et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther 2006, 28:1619-1629.
29. Schwartz S., Hassman D., Shelmet J., et al. A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge × 6 mm needle versus a 29 gauge × 12.7 mm needle in obese patients with diabetes mellitus. Clin Ther 2004, 26:1663-1678.
30. Korytkowski M., Bell D., Jacobsen C., et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003, 25:2836-2848. FlexPen Study Team.
31. Carter J., Beilin J., Morton A., De Luise M. Usability, participant acceptance, and safety of a prefilled insulin injection device in a 3-month observational survey in everyday clinical practice in Australia. J Diabetes Sci Technol 2009, 3:1425-1438.
32. Verdun di Cantogno E., Russell S., Snow T. Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence 2011, 5:173-180.
33. Gilmartin C. Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. Am J Health Syst Pharm 2007, 64(Suppl 8):S15-S22.